Northeast Ohio-based CELLTRION INC. announced today that the U.S. FDA granted approval for a substantial new entity, triggering a significant market opportunity for the biotechnology giant and potentially reshaping the competitive landscape in its therapeutic space. The regulatory milestone solidifies CELLTRION's leadership in the sector, likely driving a surge in investor interest and paving the way for expanded commercial dominance, particularly upon the anticipated launch of the product later this year.